^
    Back
    Association details:
    Biomarker:IGH mutation
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Brukinsa (zanubrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    IWCLL 2023
    Title:

    Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study

    Published date:
    10/06/2023
    Excerpt:
    With additional follow-up, PFS with zanubrutinib vs BR was improved for patients with mutated IGHV (HR, 0.35; 95% CI, 0.19–0.64)…
    DOI:
    https://doi.org/10.1080/10428194.2023.2250219
    Trial ID:
    SEQUOIA